Additionally, the tumor weight, infiltration level, and anti‐tumor activity of CD8+ T cells in the shNC tumors treated with anti‐CCL20 antibody were comparable to those in the shGal1 tumors treated with anti‐CCL20 antibody (Figure 4F,I–K). The gene discussed is CCL20; the disease is neoplasm.